TickerFacts.

Neurogene Inc. (NGNE): Revenue

Annual figures by period end, from SEC filings.

$0
Year ended 2025-12-31
$25.00M2018-12-31: $25.00M2023-12-31: $02024-12-31: $925.0K2025-12-31: $0$0
2018-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$0-100.0%2026-03-24, From 2025-01-01
2024-12-31$925.0Kn/a2026-03-24, From 2024-01-01
2023-12-31$0n/a2025-03-24, From 2023-01-01
No annual figure between 2018-12-31 and 2023-12-31.
2018-12-31$25.00Mn/a2020-03-12, From 2018-01-01

Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Neurogene Inc. (NGNE)2025-12-31$0-100.0%
Abbott Laboratories (ABT)2025-12-31$44.33B+5.7%
Bristol Myers Squibb Co (BMY)2025-12-31$48.19B-0.2%
TherapeuticsMD, Inc. (TXMD)2025-12-31$3.02M+71.6%
Eli Lilly & Co (LLY)2025-12-31$65.18B+44.7%
Pfizer Inc (PFE)2025-12-31$62.58B-1.6%
Johnson & Johnson (JNJ)2025-12-28$94.19B+6.0%
Nature's Sunshine Products Inc (NATR)2025-12-31$480.14M+5.7%
Merck & Co., Inc. (MRK)2025-12-31$65.01B+1.3%

Compare NGNE, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗